Clinical trial NCT02934256: Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Official title: Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Vestibular Schwannoma
Neurofibromatosis Type 2
Keywords: Neurofibromatosis Type 2
Vestibular Schwannoma
Other NF2-related tumors
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
Collaborators: name: Betta Pharmaceuticals Co., Ltd.
First posted: 2016-10-14
Enrollment: 10
Sex: ALL
Minimum age (years): 16
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: 1)Preliminarily evaluate the treatment effect of Icotinib Hydrochloride Tablets on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of Icotinib; 3)Provide an objective basis for an enlarged randomized double-blind trial.

Detailed description: Neurofibromatosis type 2 (NF2) is a hereditary tumor predisposition syndrome caused by mutations in the NF2 tumor suppressor gene. Individuals with NF2 have a higher likelihood to develop multiple nervous system tumors, including schwannomas, meningiomas, and ependymomas. The hallmark of NF2 is bilateral vestibular schwannomas. Historically, most NF2 patients experience complete hearing loss either from tumor progression or after treatment of the tumors with surgery or radiation. Effective treatments are urgently needed for NF2 patients with progressive hearing loss because hearing loss is associated with impairment in social, emotional,and communication function and with increased depression.

Previous studies of NF2 patients treated with Erlotinib suggested that inhibition of epidermal growth factor receptor (EGFR) could result in hearing improvement and reduction in tumor size.

Much evidence implicates human epidermal growth factor (HER) receptors in vestibular schwannoma growth.Some studies have demonstrated that Merlin, the NF2 gene protein product, controls surface availability of the EGFR, ErbB2, and ErbB3 receptors in human and Drosophila models. Besides, cell culture models of mouse embryo fibroblasts (MEFs) support the role of EGFR in NF2-associated tumorigenesis. Nf2-deficient cells in culture lack contact-dependent inhibition of growth and continue to grow in confluent cultures. This effect appears to be mediated by EGFR signaling. Treatment of Nf2-deficient cells with EGFR inhibitors such as gefitinib can restore contact-dependent inhibition, suggesting that this class of drugs might be useful for NF2 patients with progressive vestibular schwannomas. In this way, Icotinib can inhibit the nutrition of the tumor and decrease the tumor's growth and metastasis. Based on these studies, we perform this clinical trial to known the treatment effect and tolerability of Icotinib on NF2.

Eligibility criteria: Inclusion Criteria:

1. Patients must be at the age of 16-50
2. Patients must meet the diagnostic criteria for NF2, with bilateral acoustic neuroma and other central nervous system tumors
3. Patients must not be treated with other drugs or radiation therapy recently
4. Patients should live in Beijing or nearby and can be treated in hospital
5. Patients must be healthy and not be seriously allergic with biological agents
6. Patients must join the clinical trial voluntarily, with good compliance, cooperate with the researchers well, sign a written informed consent.

Exclusion Criteria:

1. Treated with other drugs, surgery or radiation therapy recently
2. Brainstem is compressed seriously, with hydrocephalus, need to be treated with surgery in short time
3. Being pregnant or try to get pregnant, lactating women
4. With acute or chronic infectious diseases
5. With heart diseases, cardiac dysfunction or abnormal ECG
6. With uncontrolled neural or mental diseases, poor compliance
7. Not available for enhanced MRI
8. Take part in any other clinical trial
9. With other conditions that are considered not suitable for this clinical trial.

Primary outcomes:
measure: Change from Baseline in volume of tumour after every course of the treatment
timeFrame: Baseline,Month 3,Month 6,Month 9,Month 12
Secondary outcomes:
measure: Change from Baseline in hearing ability after every course of the treatment
timeFrame: Baseline,Month 3,Month 6,Month 9,Month 12
Other outcomes:
measure: Change from baseline in QOL(quality of life) score after every course of the treatment
timeFrame: Baseline,Month 3,Month 6,Month 9,Month 12
Locations:
city: Beijing
country: China
facility: Beijing Tiantan Hospital Affiliated to Capital Medical University
state: Beijing
city: Beijing
country: China
facility: Beijing Tiantan Hospital Affiliated to Capital Medical University
Study officials:
affiliation: Beijing Tiantan Hospital
name: Pinan Liu
role: STUDY_DIRECTOR
affiliation: Beijing Neurosurgical Institute
name: Fu Zhao
role: PRINCIPAL_INVESTIGATOR
References: